U.S. Department of Health and Human ServicesHHS National Institutes of HealthNIH National Center for Advancing Translational SciencesNCATS
Home
Share Page
Email a link to this page.
Share this page on Facebook.
Share this page on Twitter.
  • Home
  • Get Started
    • Learn About Registries
    • Understand Data Principles
    • Learn About Ethical and Legal Aspects
    • Know Your Disease Landscape
  • Set Up Your Registry
    • Create Your Registry Plan
    • Determine Who Should Join
    • Develop the Right Questions to Ask
    • Decide How to Collect & Store Your Data
  • Manage Your Registry
    • Recruit & Engage Participants
    • Review & Clean Your Data
    • Promote Your Registry
    • Review & Evolve Your Registry
  • Glossary
  • About RaDaR
  • Academic researcher
  • Active-comparator arm
  • Adaptive design
  • Adeno-associated virus
  • Adeno-associated virus gene therapy
  • Adeno-associated virus vector capsid
  • Adverse event
  • Antisense oligonucleotide
  • Arm
  • Assay
  • Attribute
  • Basic research
  • Basket protocol
  • Bias
  • Bioassay
  • Biologic
  • Biomarker
  • Biopharmaceutical industry
  • Biorepository
  • Biosample
  • Biotechnology
  • Blinded observations
  • Blinding
  • Caregiver
  • Caregiver perspective
  • Caregiver preference
  • Cell therapy
  • Center for Biologics Evaluation and Research
  • Center for Drug Evaluation and Research
  • Clinical data
  • Clinical investigator
  • Clinical outcome
  • Clinical outcome assessment
  • Clinical relevance
  • Clinical research
  • Clinical research coordinator
  • Clinical researcher
  • Clinical study design
  • Clinical study participant
  • Clinical study protocol
  • Clinical study sponsor
  • Clinical trial
  • Clinician-reported outcomes (ClinRO)
  • Co-investigator (Co-I)
  • Co-principal investigator (Co-PI)
  • Common data element
  • Community-based clinical trial (CBCT)
  • Comparative effectiveness research (CER)
  • Compliance
  • Confidentiality
  • Conflict of interest
  • Contact registry
  • Contract
  • Contraindication
  • Control arm
  • Controlled access data sharing
  • Core common data element
  • CRISPR-Cas gene editing system
  • CRISPR-Cas9
  • Crossover study
  • Data
  • Data access
  • Data analysis
  • Data analysis plan
  • Data cleaning
  • Data element (DE)
  • Data management
  • Data management plan
  • Data monitoring
  • Data Monitoring Committee
  • Data ownership
  • Data quality
  • Data sharing
  • Data sharing agreement
  • Data standard
  • Data summary
  • Database
  • Dataset
  • De-identified patient data
  • De-identify
  • Demographic data
  • Diagnostic criteria
  • Disease model
  • Disease-specific common data element
  • Domain-specific common data element
  • Double-blind study
  • Dropout statistical analysis
  • Drug
  • Drug-drug interaction
  • Early phase 1
  • Effectiveness
  • Effectiveness study
  • Efficacy
  • Electronic medical record
  • Eligibility criteria
  • Endpoint
  • Exclusion criteria
  • Experimental arm
  • Exploratory common data element
  • Factorial assignment
  • Fibroblast
  • Follow-up duration
  • Gene therapy
  • Genome editing
  • Group sequential trial
  • Health consumer
  • Health Insurance Portability and Accountability Act
  • Imaging data
  • Implementation study
  • Inclusion criteria
  • Induced pluripotent stem cell
  • Informed consent
  • Informed consent form
  • Informed consent process
  • Institutional Review Board
  • Intervention
  • Intervention model
  • Investigational New Drug
  • Investigational New Drug Application
  • Investigational therapy
  • Laboratory data
  • Longitudinal study
  • Marketing authorization
  • Master protocol
  • Median effective dose
  • Medical device
  • Multiple principal investigators
  • Natural history study
  • New Drug Application
  • Newborn Screening
  • Observational study
  • Observational Study Monitoring Board
  • Observer-reported outcomes
  • Office of Orphan Products Development
  • Open access data sharing
  • Organoid
  • Orphan drug
  • Parallel study
  • Pathophysiology
  • Patient
  • Patient advocate
  • Patient engagement
  • Patient experience data
  • Patient investigator
  • Patient perspective
  • Patient preference
  • Patient preference information
  • Patient preference studies
  • Patient-provided input
  • Patient registry
  • Patient-reported outcome
  • Personally identifiable information
  • Pharmaceutical Industry
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phases of Clinical Trials
  • Physical functioning data
  • Placebo
  • Placebo comparator arm
  • Placebo controlled study
  • Placebo effect
  • Platform protocol
  • Population group
  • Population-specific safety
  • Preclinical studies
  • Prevention trials
  • Primary outcome measure
  • Primary purpose
  • Principal investigator
  • Principal investigator
  • Protected health information
  • Protected personally identifiable information
  • Proteomics
  • Protocol-specific data elements
  • Qualitative data
  • Quantitative data
  • Randomization
  • Randomized controlled trial
  • Real-world data
  • Real-world evidence
  • Registry
  • Registry governance plan
  • Registry platform
  • Registry sustainability
  • Regulator
  • Reliability
  • Representativeness
  • Required common data element
  • Results database
  • RNA transcript
  • Screening Trials
  • Secondary outcome measure
  • Serious adverse event
  • Sex
  • Sham comparator arm
  • Single-blind study
  • Single group study
  • Small molecule drug
  • Stakeholder
  • Standardization
  • Statistical analysis plans
  • Statistical power analysis
  • Statistical significance
  • Study outcome measurement
  • Subgroup
  • Supplemental common data element
  • Supplemental-highly recommended common data element
  • Supportive care
  • Supportive care trial
  • Surrogate endpoint
  • Survey data
  • Therapeutic target
  • Toxicity
  • U.S. Food and Drug Administration
  • Umbrella protocol
  • Unblinding
  • Underserved group
  • Universal common data element
  • Unmet medical need
  • Validation
  • Validity
  • About RaDaR
  • Home
  • Glossary
  • Disclaimer
  • Sitemap
  • HHS Vulnerability Disclosure
  • FOIA
  • OIG
gard-logo-white.png
radar-logo-white.png
toolkit-logo-white.png

Maintained by the National Center for Advancing Translational Sciences (NCATS)